Can biomarkers help us hit targets in difficult-to-treat asthma? (Q38752058)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

Can biomarkers help us hit targets in difficult-to-treat asthma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Liam G Heaney

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

1 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

430-442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

Severe asthma treatment: need for characterising patients

4 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The prevalence of nonadherence in difficult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The relationship between clinical outcomes and medication adherence in difficult-to-control asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The prevalence of severe refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Medication adherence and the risk of severe asthma exacerbations: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Non-adherence in difficult asthma: time to take it seriously

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Detailed analysis of sputum and systemic inflammation in asthma phenotypes: are paucigranulocytic asthmatics really non-inflammatory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Enhanced innate type 2 immune response in peripheral blood from patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Evolving Concepts of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Targeting the interleukin pathway in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Induced sputum: validity of fluid-phase IL-5 measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Full blood count parameters for the detection of asthma inflammatory phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Periostin levels and eosinophilic inflammation in poorly-controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Current evidence and future research needs for FeNO measurement in respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Effects of steroid therapy on inflammatory cell subtypes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Use of exhaled nitric oxide measurements to guide treatment in chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Non-eosinophilic cor ticosteroid unresponsive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

21 January 2018

Lessons from LAVOLTA.

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Systemic upregulation of neutrophil α-defensins and serine proteases in neutrophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.13014

21 January 2018

Identifiers

DOI

10.1111/RESP.13014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28248008%20AND%20SRC:MED&resulttype=core&format=json